Novo Nordisk and Hims & Hers Settle Patent Dispute, Collaborate on Weight Loss Medications | Johnson & Johnson Forecasts Profit Growth Despite Drug Pricing Deal | Eli Lilly Invests $6 Billion in Alabama Pharmaceutical Facility | Pfizer Acquires Metsera for $10 Billion Amidst Bidding War | Merck Scraps £1 Billion UK Expansion Amid Investment Concerns | Merck Scraps London Research Center, Citing UK Investment Concerns | AstraZeneca to Invest $50 Billion in the U.S. | Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity | Novo Nordisk and Hims & Hers Settle Patent Dispute, Collaborate on Weight Loss Medications | Johnson & Johnson Forecasts Profit Growth Despite Drug Pricing Deal | Eli Lilly Invests $6 Billion in Alabama Pharmaceutical Facility | Pfizer Acquires Metsera for $10 Billion Amidst Bidding War | Merck Scraps £1 Billion UK Expansion Amid Investment Concerns | Merck Scraps London Research Center, Citing UK Investment Concerns | AstraZeneca to Invest $50 Billion in the U.S. | Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity
Novo Nordisk and Hims & Hers have resolved their legal battle over patent infringement, paving the way for a collaboration that will bring Novo Nordisk's popular weight loss medications, Ozempic and Wegovy, to the Hims & Hers platform. This...
Image via CNBC
Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs
